Full-Time
Field Service Engineer
Bruker
1,001-5,000 employees
Manufactures analytical instruments for NMR diagnostics
Compensation Overview
$85k - $137k/yr
Boston, MA, USA
In Person
Approximately 70% travel required; must live near a major airport.
Bachelor's
 Hardware Engineering (2) |
|---|
| , |
Get referred to Bruker
See people who can refer or advise you
- A Bachelor of Science degree in Electrical Engineering, Electronics, or a related discipline, or equivalent military training.
- At least four years of experience diagnosing and repairing electronic, electromechanical, and optically aligned equipment.
- Knowledge of analog electronics, high-voltage circuitry, laser technology, and analytical instrumentation.
- Strong verbal, written, computer, technical data, communication, and presentation skills, including knowledge of Transmission Control Protocol/Internet Protocol protocols.
- A valid driver's license issued by the state of residence and a good driving record.
- Ability to work independently, organize and prioritize work, multitask, follow through, and meet deadlines.
- Ability and willingness to travel approximately 70% as required.
- Eligibility under applicable export control restrictions.
- Install, test, and provide customer training for Fourier Transform Infrared spectrometers.
- Set up instruments and verify that systems meet factory specifications through Instrument, Operational, and Performance qualifications using calibrated standards when required.
- Secure customer acceptance of installations and repairs.
- Diagnose problems through in-depth troubleshooting and repair complex optical instruments.
- Re-qualify instruments after service or repair to ensure proper performance.
- Perform on-site preventive maintenance and validation of spectrometers.
- Organize and prioritize schedules according to customer requirements, including immediate attention, on-site visits, and remote assistance.
- Coordinate WebEx sessions, phone support, and laboratory facility inspections for new installations.
- Coordinate travel arrangements.
- Attend in-depth product training at the Bruker Optics facility in Germany.
- Communicate and work closely with Service and Support Centers.
- Perform other duties as required.
- Experience with Fourier Transform Infrared spectrometers.
Bruker makes analytical and diagnostic instruments used by researchers and industries. Its products help analyze materials and biological samples to reveal chemical structure, composition, and properties, with notable roots in nuclear magnetic resonance (NMR) technology and a broad portfolio beyond that field. The company works by designing and selling instruments such as analytical tools that collect data from samples (for example, signals from nuclei in NMR or other spectroscopic methods) and provide insights to researchers. Bruker differentiates itself through a long history of developing advanced technologies, a focus on innovation in scientific instrumentation, and a global product range serving life sciences, materials science, and environmental analysis, supported by steady investment in research and development. Its goal is to equip researchers and industries with reliable tools to push the boundaries of what is possible in science and discovery.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Billerica, Massachusetts
Founded
1960
Get referred to Bruker
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 Scientific Instruments bookings rose 10% organically, with book-to-bill above 1.0x.
- Q2 2026 revenue reached $838.5 million, with organic growth returning after four declines.
- May 2026 BioSpec 18T MRI and August 2026 detector launches strengthen premium leadership.
What critics are saying
- Q2 2026 goodwill impairments of $134.9 million signal fragile acquisition valuations.
- Bruker completed 2025 restructuring, then launched another BSI NANO cut in 2026.
- Patent settlements with 10x Genomics and AbCellera drain cash and expose hostile litigation.
What makes Bruker unique
- Bruker spans instruments, spatial biology, and diagnostics across one integrated workflow stack.
- On 2026-08-10, Bruker bought MIMETAS, adding organ-on-chip disease models.
- On 2026-08-11, Bruker tied Atinary self-driving labs to Chemspeed, SciY, and NMR.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Disability Insurance
Life Insurance
Dental Insurance
Flexible Work Hours
Employee Discounts
Growth & Insights and Company News
6 month growth
↑ 14%1 year growth
↑ 14%2 year growth
↑ 14%Bruker takes majority stake in dutch MIMETAS as organoid technologies move into the mainstream. The U.S. analytical technology group is acquiring a majority stake in Dutch organ-on-a-chip specialist MIMETAS, bringing human tissue models into its broader portfolio of multiomics, spatial biology and preclinical imaging. The deal is another sign that organoids and microphysiological systems are moving from specialized research tools toward integrated platforms for drug discovery. Bruker is expanding its life sciences business into human physiology-relevant disease models with a majority investment in MIMETAS, a Leiden-based developer of organ-on-a-chip platforms and advanced human tissue models. Financial terms were not disclosed. MIMETAS will continue to operate under its existing brand and management. The strategic logic is straightforward: MIMETAS provides the human tissue models, while Bruker brings technologies for proteomics, metabolomics, NMR, spatial biology and preclinical imaging. The companies aim to connect the two into integrated workflows for disease research, compound testing and drug development. MIMETAS' flagship OrganoPlate platform uses microfluidic tissue cultures in a format compatible with standard high-throughput laboratory workflows. Its portfolio includes models for vascularized tissues, liver, lung and gut, as well as organoid-derived models. The company also offers OrganoReady tissue and organoid products, instrumentation and contract research services. "Human physiology-relevant tissue and disease models are becoming increasingly important for understanding disease biology and evaluating therapeutic candidates," Bruker CEO Frank H. Laukien said. He described microphysiological systems (MPS), also known as New Approach Methodologies (NAMs), as having a "bright future" in drug discovery, development and preclinical testing. From organoids to industrial workflows. The MIMETAS transaction matters because it is less about a single organoid model than about the industrialization of human-relevant biology. Organoids, 3D microtissues and organ-on-a-chip systems can reproduce aspects of human tissue architecture and function that are difficult to capture with conventional two-dimensional cell cultures. In drug development, their potential applications range from target validation and disease modeling to efficacy and toxicity testing. They are not, however, a universal replacement for animal studies. Standardization, reproducibility, scalability and the ability of individual models to predict clinical outcomes remain important challenges. The growing interest in combining these models with automated screening, imaging and molecular profiling reflects an attempt to address some of those limitations. That is where Bruker's position becomes particularly relevant. Instead of simply adding another cell model to its portfolio, the company can connect human tissue systems with increasingly sophisticated molecular and spatial readouts. The resulting data could ultimately feed into computational and AI-based drug discovery workflows. Europe is already consolidating the field. Bruker's move also fits into a broader European consolidation of technologies around organoids, 3D cell models and advanced in-vitro testing. Merck KGaA acquired Dutch organoid specialist HUB Organoids in late 2024. The Utrecht-based company developed organoid technologies that complement Merck's existing life sciences portfolio of cell culture products, reagents and research tools. Sartorius made a similar move in 2025, agreeing to acquire MatTek, including Visikol, from Swedish BICO Group for $80 million. The transaction added 3D microtissue models and primary cells to Sartorius' cell technology portfolio. MatTek's models are designed to mimic human tissue structure and function and complement Sartorius' cell analysis instruments, reagents and AI-supported models. Sartorius completed the acquisition on July 1, 2025. The transaction also illustrates a wider reshaping of the sector. BICO itself had acquired MatTek in 2021 but later decided to divest the business as it refocused on lab automation and selected workflows. In other words, the technology is moving in two directions at once: specialist companies are developing increasingly sophisticated human models, while larger life sciences companies are integrating those models into broader laboratory and drug-development ecosystems. A European strength with global ambitions. There is a notable European footprint in this emerging market. MIMETAS and HUB Organoids are both Dutch companies, while Sartorius has built its cell technology strategy around its German base. Switzerland's InSphero, meanwhile, has established itself as another major European player in 3D cell and microtissue models. Roche is building its own research institute to develop organoids. There are loads of companies around in UK, Germany (TissUse, Cellbricks in Berlin), Austria (a:head, HeartBeat.Bio in Vienna), in Scandinavia and elsewhere working on special plattform technologies or using organoids for drug development themselves like Indivumed in Hamburg. This gives Europe a meaningful position in a field that sits at the intersection of biotechnology, laboratory technology and drug development. The regulatory environment is also moving in the same direction, although adoption remains uneven. The broader NAM concept encompasses technologies ranging from organoids and organ-on-a-chip systems to computational models and other human-relevant approaches intended to improve or reduce the use of traditional animal testing. The real prize is the data. For Bruker, the long-term opportunity may therefore lie less in selling organoids than in capturing better biological data from them. A human tissue model becomes considerably more valuable when it can be combined with automated experiments, high-content imaging, spatial biology, proteomics and metabolomics. That creates a potential feedback loop in which increasingly human-relevant models generate increasingly detailed datasets for drug discovery and, eventually, AI models. This is also why the MIMETAS deal belongs in the wider conversation about the changing infrastructure of drug R&D. The industry is gradually moving away from isolated tools toward connected platforms that link biology, measurement, automation and computation. Bruker's investment in MIMETAS is another indication that organoids and microphysiological systems are no longer being viewed simply as promising alternatives to conventional cell culture. They are increasingly becoming part of the commercial infrastructure for the next generation of drug discovery.
Enables deeper integration of Atinary's SDLabs platform with Chemspeed automation, Bruker instruments and SciY software for closed-loop agentic AI-driven RD Bruker Corporation (Nasdaq: BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs (r) technologies and AI-driven RD with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also made a minority investment in Atinary. Financial details were not disclosed. Atinary Self-Driving Lab integrating Chemspeed robotics, a Fourier 80 FT-NMR, and Atinary's SDLabs agentic AI platform into a closed-loop workflow. The system automates liquid and solid reagent addition, catalyst addition, reaction execution, sampling with filtration, and inline NMR analysis, across many chemical reactions, including Suzuki and Buchwald-Hartwig. Scientists control the platform via SDLabs, leveraging AI agents to design experiments, navigate molecular spaces,
Bruker Corporation announced a strategic investment in Atinary Technologies, a pioneer in self-driving laboratory technologies and AI-driven research and development. Financial terms were not disclosed. The collaboration will integrate Chemspeed automation platforms, Bruker analytical instruments, and SciY software into Atinary's SDLabs platform. This system uses AI agents and machine learning to design experiments and automate workflows across pharmaceuticals, chemicals, energy, and materials sectors. Atinary and Chemspeed have established a joint demonstration laboratory near Basel, Switzerland. Atinary's Boston facility, which opened in early 2026, focuses on small-molecule synthesis and catalysis for pharmaceutical development. The partnership aims to accelerate scientific discovery by combining lab automation with AI-guided experimentation. Each experiment generates data to improve subsequent research outcomes.
Bruker Corporation has announced a majority investment in MIMETAS B.V., a Dutch developer of organ-on-a-chip platforms and human tissue models for drug discovery and development. The deal expands Bruker's portfolio into Microphysiological Systems, which use human physiology-relevant model systems for disease research. MIMETAS develops scalable organ-on-a-chip platforms that enable researchers to study disease mechanisms in perfused, biologically relevant systems. Its OrganoPlate platform combines standard microtiter-plate format with membrane-free microfluidic tissue cultures, supporting imaging and automated workflows. Bruker plans to integrate MIMETAS' capabilities with its existing technologies in proteomics, metabolomics, NMR, preclinical imaging and spatial biology. The companies intend to develop integrated workflows connecting human model systems with Bruker's molecular and cellular characterisation technologies and services.
Press Release / Bruker Announces Major Advances in Detector Technology for Semiconductor, Thin Film... - Electronics / Instrumentation / RFID - Bruker Corporation. Discover more Advertising Business Operations NewswireToday Economics sales news public relations Advertise Business Formation / | Bruker Announces Major Advances in Detector Technology for Semiconductor, Thin Film, Energy Materials and Nanostructure Characterization | | / | PRZOOM - /newswire/ - Milwaukee, WI, United States, 2026/08/03 - New detectors enable multimodal SEM analysis with breakthrough performance - Bruker.com. NASDAQ: BRKR | | / | Your Banner Ad Here instead - Showing along with ALL Articles covering Electronics / Instrumentation / RFID Announcements Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How! | | / | Bruker today announced the launch of two groundbreaking detectors at Microscopy & Microanalysis (M&M) 2026: the eWARP(TM) TKD, a next-generation Transmission Kikuchi Diffraction (TKD) detector for nanoscale crystallographic characterization, and the XFlash(R) FlatQUAD(TM) 2L, the latest evolution of Bruker's annular EDS detector, enabling simultaneous Energy Dispersive X-ray Spectroscopy (EDS) and Back-Scattered Electron (BSE) detection. These innovations redefine the possibilities of Scanning Electron Microscope (SEM)-based characterization by compounding breakthrough speed, sensitivity, spatial resolution, and multimodal analytical capabilities. Building on Bruker's unique eWARP technology, the eWARP TKD brings the advantages of Direct Electron Detection (DED) with Wide ARea Pixelated (WARP) sensors to TKD in SEMs. The detector combines a new 162 x 162 pixel sensor with a large 26 x 26 mm^2 active area and acquisition speeds up to 5,700 frames per second for unprecedented productivity and data quality. Exceptional sensitivity and ultrafast readout enable the acquisition of diffraction data up to an order of magnitude faster than with conventional TKD. Combined with a state-of-the-art field-emission SEM, eWARP TKD delivers sub-2 nm spatial resolution, enabling researchers to characterize semiconductor structures, thin films, 2D materials, energy materials, and nanostructured alloys acquired over larger areas than before. Bruker's patented on-chip binning allows integrated Dark-Field- and Bright-Field-like imaging at unmatched speed, providing complementary microstructural information and real-time observation of material changes during in-situ experiments. The new XFlash(R) FlatQUAD(TM) 2L enables industry-leading EDS efficiency with simultaneous BSE imaging. Utilizing Bruker's unique annular four-segment Silicon Drift Detector (SDD) between SEM pole piece and sample, the XFlash(R) FlatQUAD 2L enables direct correlation of elemental composition and contrast. Acquiring EDS and BSE simultaneously accelerates characterization workflows, reduces electron dose on sensitive samples, and obtains perfectly co-registered multimodal datasets. The combination is particularly valuable for heterogeneous and multiphase materials, semiconductor devices, battery electrodes, nanoparticles, biological specimens, and FIB lamellae, where rapid identification of elemental distributions, interfaces, contamination, coatings, defects, and degradation mechanisms is critical. "The eWARP TKD represents a major leap forward in quantitative nanoscale characterization in SEMs," said Daniel Goran, Senior Product Manager EBSD at Bruker. "By combining DED with our industry-leading on-axis TKD approach, the eWARP TKD allows researchers to characterize nanostructured materials faster, over larger areas, and with greater confidence than ever before." "The XFlash(R) FlatQUAD 2L changes the acquisition of analytical data in SEMs," added Andi Kaeppel, Senior Product Manager EDS/SEM at Bruker. "The ability to collect perfectly correlated EDS and BSE information gives a more complete understanding of complex materials, while simplifying and accelerating their workflows." These innovations reinforce Bruker's position at the forefront of SEM detector development, delivering the technologies researchers need to better understand increasingly complex materials and devices. About Bruker Corporation Leader of the Post-Genomic Era Bruker (bruker.com) is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with its customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy, as well as in industrial and cleantech research, and semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, proteomics and multiomics, spatial and single-cell biology, structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. | | / | Your Banner Ad Here instead - Showing along with ALL Articles covering Electronics / Instrumentation / RFID Announcements Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How! | | / | Agency / Source: Bruker Corporation | | / | Availability: All Regions (Including Int'l) | | / | Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker | | / | Distribution / Indexing: [+] / [Company listed above is a registered member of its network. Content made possible by PRZOOM / PRTODAY indexing services] | | / | # # # | | / | Your Banner Ad showing on ALL Electronics / Instrumentation / RFID articles, CATCH Visitors via Your Competitors Announcements! Company website links NOT available to basic submissions | / | It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source. | | / | For more information, please visit: Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now! eWARP TKD Detector | Bruker Corporation | Contact: Dr. Heiko Ress - Bruker.com +49 721 50997-0 heiko.ress[.]bruker.com | PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT PRZOOM. Issuers of articles are solely responsible for the accuracy of their content. Its complete disclaimer appears here. IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bruker Corporation securities in any jurisdiction including any other companies listed or named in this release. | Discover more Public Relations newswireToday Journalism & News Industry Business & Industrial News Sales market search business | Read Latest Press Releases From Bruker Corporation / Company Profile | Read Electronics / Instrumentation / RFID Most Recent Related Press Releases: | (C) 2005-2026 PRZOOM - Limelon Advertising, Co. Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS | | newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today PRZOOM use cookies to enhance your experience. By continuing to visit this site you agree to its use of cookies. More info